No ATTR-silencer is currently approved for the treatment of patients with ATTR-CM, whereas two gene silencers are currently approved for the treatment of patients with ATTRv polyneuropathy, either with or without cardiac involvement: patisiran and inotersen. The gene discussed is TTR; the disease is polyneuropathy.